Boltz Lab now a daily tool for pharma scientists; partners include Pfizer, GSK, Takeda, BMS
GabriCorso · x · 2026-11-18
Boltz says scientists use Boltz Lab daily from target validation to lead optimisation, overcoming bottlenecks on hard targets and accelerating discovery programmes.
The team stresses that models this powerful should be accessible to every scientist, not locked behind one company's pipeline or restrictive strategic partnerships. Partners now include Pfizer, GSK, Takeda and BMS.
More from Venture
- SEO consultant pitches 14 journalists a week, calls GEO "BS" — gaganghotra_ · 2026-11-18
- Boltz's long-term goal: hypothesis to human-ready molecule without leaving the computer — GabriCorso · 2026-11-18
- Boltz raises $110M Series A for AI biomolecular design, partners with 6 top-20 pharma giants — GabriCorso · 2026-11-18
- Anthropic IPO: $70-78/share, up to ~$1.4T valuation, ~$90B raise with supplier private placement — RihardJarc · 2026-11-18
- Traders Buy Anthropic at $1.8T Valuation on Pre-IPO Perps, Calling It a No-Brainer — adamamcbride · 2026-11-18
- Analyst: Anthropic stake could exceed 20% of Amazon's market cap within weeks — RihardJarc · 2026-11-18